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Abstract
Background: Previous randomized trials have showed the superiority of Paclitaxel-eluting stent
over bare metal stent in angiographic and clinical outcomes. Coroflex Please™ stent is a newly
developed drug eluting stent using the Coroflex™ stent platform combined with the drug paclitaxel
contained in a polymer coating. PECOPS I trial, one-arm observational study, showed that the
clinical and angiographic outcomes of Coroflex Please™ stent were within the range of those of
Taxus, the 1st generation paclitaxel-eluting stent (PES). However, there have been no studies
directly comparing the Coroflex Please™ stent with the Taxus Liberte™ stent that is the newest
version of Taxus. Therefore, prospective, randomized trial is required to demonstrate the non-
inferiority of Coroflex Please™ stent compared with Taxus Liberte™ stent in a head-to-head
manner.
Methods: In the comparison of Efficacy between COroflex PLEASe™ ANd Taxus™ stent(ECO-
PLEASANT) trial, approximately 900 patients are being prospectively and randomly assigned to the
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either type of Coroflex Please™ stent and Taxus Liberte™ stent via web-based randomization.
The primary endpoint is clinically driven target vessel revascularization at 9 months. The secondary
endpoints include major cardiac adverse events, target vessel failure, stent thrombosis and
angiographic efficacy endpoints.
Discussion: The ECO-PLEASANT trial is the study not yet performed to directly compare the
efficacy and safety of the Coroflex Please™ versus Taxus Liberte™ stent. On the basis of this trial,
we will be able to find out whether the Coroflex Please™ stent is non-inferior to Taxus Liberte™
stent or not.
Trial registration: ClinicalTrials.gov number, NCT00699543.
Background
Previous randomized trials have shown the efficacy of a
slow-release polymeric sirolimus-eluting stent (Cypher™,
Cordis, Warren, NJ, USA), paclitaxel-eluting stent
(Taxus™, Boston Scientific, Natick, MA, USA), and zotar-
olimus-eluting stent (Endeavor™, Medtronic, Minneapo-
lis, MN, USA) over bare metal stents in reducing
neointimal hyperplasia, late luminal loss, and angio-
graphic restenosis leading to decreased target lesion revas-
cularization [1-11] The Paclitaxel-eluting Coroflex
Please™ stent is a newly developed drug eluting stent using
the Coroflex® stent platform combined with the drug pacl-
itaxel contained in a polymer coating[12]
In the PECOPS I, which was one-arm observational study,
the results of Coroflex Please™ stent were within the range
of other Paclitaxel-eluting coronary stents [12,13] Com-
pared with binary restenosis rate of 7.9% in Taxus IV trial,
Coroflex™ Please stent showed 7.8% of restenosis rate[7]
The 3.1% of 30 day MACE rate is within the range of other
trials with stents eluting Paclitaxel or Sirolimus. The 6
month MACE rates in PECOPS I were 8.0%, which was
similar to 7.8%, and 8.5% in Taxus II MR and SR, respec-
tively[6] In Taxus IV, 9 month follow up revealed a MACE
rate of 8.5%[7] In Taxus ATLAS trial, Taxus Liberte™ stent
was proved to be non-inferior to TAXUS Express™ with 9
month TVR 8.0%[14] (Table 1) In other words, the effi-
cacy of Coroflex Please stent has not been evaluated in
wide range of lesion complexity met in the real world and
not been compared with the similar taxol-eluting stents
like Taxus stent.
Therefore, this study will compare the effectiveness and
safety of the Coroflex Please™ stent versus the newest ver-
sion Taxus Liberte™stent in patients with coronary disease
including several lesion types that were excluded in previ-
ous clinical trial of PECOPS I to evaluate its efficacy and
safety on relatively less-selected and more-"real-world"
lesions.
Study Objectives
The primary objective of this study is to evaluate the clin-
ical efficacy, angiographic outcomes and safety of coro-
nary stenting with the Coroflex Please™ stent system (B
Braun, Germany), compared with the Taxus Liberte™ stent
system (Boston Scientific, USA) in the treatment of coro-
nary stenosis.
Methods
Study Design
This trial will be a prospective, randomized, open label,
multi-center trial to demonstrate the non-inferiority of
Coroflex Please™ stent compared with Taxus Liberte™
stent in "real world" coronary lesions.
Table 1: Angiographic characteristics of Studies with Paclitaxel-Eluting Coronary stents
Taxus IV
(N = 662)
ATLAS
(N = 871)
PECOPS I
(N = 97)
Reference, mm 2.75 2.75 2.89
MACE % (6-9 months) 8.5 11 8
TVR % (6-9 months) 4.7 8 -
TLR % (6-9 months) 3 5.7 5.7
Binary angiographic restenosis, %
In-stent 5.5 11.4 3.9
In-segment 7.9 14.3 7.8
Late loss, mm
In-stent 0.39 0.41 0.47
In-segment 0.23 0.25 -Trials 2009, 10:98 http://www.trialsjournal.com/content/10/1/98
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Patient Enrollment
915 patients will be enrolled at 17 centers in Korea. Fol-
lowing angiography, patients with significant diameter
stenosis >70% by visual estimation or patients with diam-
eter stenosis >50% by visual estimation who have docu-
mented myocardial ischemia or symptoms of angina, and
have lesions that are eligible for stenting without any
exclusion criteria, will be randomized 2:1 to either a)
Coroflex Please™ stent or b) Taxus Liberte™stent.
Patient Follow-up
Clinical follow-up will be at 1, 4, 9, 12 months and 2, 3
years after intervention. The investigator may conduct fol-
low-up as telephone contacts or office visits. An angio-
graphic follow-up will be required at 9 months to
determine late luminal loss. Late angiographic follow-up
will be recommended at 18-24 months post PCI in
patients enrolled at selected centers.
Endpoints
The primary efficacy endpoint is clinically driven Target
Vessel Revascularization (TVR) at 9 months.
Clinical safety and efficacy secondary endpoints are Major
Cardiac Adverse Events (MACE; all death, cardiac death,
myocardial infarction (Q-wave and non-Q wave), TVR),
Target Vessel Failure (TVF; cardiovascular death, myocar-
dial infarction, clinically driven TVR) and stent thrombo-
sis.
Angiographic secondary endpoints are in-stent binary res-
tenosis by QCA; in-stent and in-lesion late loss by QCA;
in-stent and in-lesion MLD and percentage diameter sten-
osis by QCA immediately after the index procedure and at
follow-up.
Patient Population
Total 915 patients derived from a population of Korean
patients receiving percutaneous coronary intervention for
ischemic heart disease will be enrolled in the present trial.
Consecutive patients presenting at participating centers
will be evaluated for the entry into the study. All consecu-
tive patients (≥ 18 years of age) with coronary artery sten-
osis >50% by visual estimation will be screened for
enrollment in this study and, if PCI is planned, should be
invited to participate in the study.
Patients ≥ 18 years will be included in this study if they
meet all of the following criteria: coronary artery stenosis
(>50% by visual estimate) with evidence of myocardial
ischemia (e.g., stable, unstable angina, myocardial infarc-
tion, silent ischemia, positive functional study or a revers-
ible changes in the electrocardiogram (ECG) consistent
with ischemia.) or significant coronary artery stenosis
(>70% by visual estimate); Target lesion(s) located in a
native coronary artery with visually estimated diameter of
≥ 2.5 mm and ≤ 4.0 mm; Target lesion(s) amenable for
percutaneous coronary intervention.
This study excludes patents with followings: hypersensi-
tivity or contraindication to the medications (heparin,
aspirin, both clopidogrel and ticlopidine, paclitaxel, stain-
less steel or contrast media); Systemic (intravenous) Pacl-
itaxel use within 12 months; Female of childbearing
potential, unless a recent pregnancy test is negative, who
possibly plan to become pregnant any time after enroll-
ment into this study; History of bleeding diathesis or
known coagulopathy (including heparin-induced throm-
bocytopenia), or willing to refuse blood transfusions;
Gastrointestinal or genitourinary bleeding within the
prior 3 months, or major surgery within 2 months; An
elective surgical procedure is planned that would necessi-
tate interruption of thienopyridines during the first 9
months post enrollment; Non-cardiac co-morbid condi-
tions are present with life expectancy <1 year or that may
result in protocol non-compliance (per site investigator's
medical judgment); Patients who are actively participat-
ing in another drug or device investigational study, which
have not completed the primary endpoint follow-up
period; Patients with LV ejection fraction <25% or those
with cardiogenic shock; Patients with acute ST elevation
myocardial infarction who requires primary PCI; Patients
with acute ST elevation myocardial infarction within 48
hrs; Creatinine level ≥ 3.0 mg/dL or dependence on dialy-
sis; Severe hepatic dysfunction (AST and ALT: 3 times
upper normal reference values); significant left main stem
stenosis which requires revascularization therapy; target
lesion has in-stent restenosis at the stented segment of
drug-eluting stents or bare metal stents; Target lesions
with bifurcating disease which require side branch stent-
ing.
Conduct of the study
After the patient has been enrolled in the present study,
the following procedures will take place. The schedule of
events for this trial is appeared in table 2. The treatment
strategy will be determined by the study-certified interven-
tional operator. It is recommended that each enrolling
investigator review the most recently updated instructions
for use (IFU) and assess the contraindications, warnings,
and precaution sections for treating potential patients.
Index PCI
After random assignment to Coroflex Please™ or Taxus
Liberte™ stents, the index PCI procedure must be carried
out in all cases with in 7 days. Staged procedures carried
out within one week will not be considered as repeat pro-
cedures. The goals of the procedure are to achieve optimal
angiographic efficacy of PCI with allocated DES in
selected target lesion sites while minimizing the risk ofTrials 2009, 10:98 http://www.trialsjournal.com/content/10/1/98
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procedure-related complications. A study-certified inter-
ventional operator should perform all PCI procedures. An
experienced catheterization laboratory staff should assist,
and backup cardiac surgical support must be available on-
site. The procedure should be performed in a cardiac cath-
eterization laboratory that is capable of providing high
quality digital images. A full range of commercially avail-
able guiding catheters, balloon catheters, and guide wires
should be readily available. PCI may be performed by the
radial or femoral approach.
Table 2: Schedule of Events
Baseline Post-Procedure Follow up
30 days 4 mo 9 mo Yearly
±2 w ± 1 m ± 3 m Up to 3 yrs
Medical/Clinical History X
Informed consent X1
Inclusion/Exlusion Criteria X
Brief Physical Examination X
Vital status X
Weight, height X
12 lead ECG X4 X
Angiogram XX X 5
CBC X
Electrolytes, LFT, Creatinine, BUN X
hs-CRP X
Fasting plasma triglycerides, HDL, total cholesterol X
Fasting glucose level2 X
HgbA1C3 X
Pregnancy test (if applicable) X
Medications XX X X X
CK, CK-MB, Troponin I6 XX
Pro-BNP or BNP X
Event monitoring XX X X X X
1The informed consent may be signed either prior to the diagnostic angiogram or after the diagnostic angiogram.
2It may be done later, before discharge when the patient is in a fasting state
3In patients with diagnosed diabetes mellitus.
4Additional ECGs will be performed at 60 ± 30 minutes post-procedure. If the patient develops recurrent chest pain, ischemia, or significant 
arrhythmias, heart failure or other signs or symptoms of clinical instability, additional ECGs should be obtained
5Routine follow up angiography will be recommended at 9 months, but it can be performed at 9 months ± 3 months. Unscheduled angiograms > 6 
months after index procedure will be considered as 9-month follow-up angiogram in final analysis.
6Optional in selected centers and if baseline lab is done, enzymes must be followed every 8-hours for 24 hours post-index procedure.Trials 2009, 10:98 http://www.trialsjournal.com/content/10/1/98
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Each procedure is preceded by a coronary angiogram of
the vessels to be treated (diagnostic angiogram). At least 2
projections of each vessel should be obtained in orthogo-
nal views. For each patient, a hierarchy of lesion priority is
established such that PCI with drug-eluting stent implan-
tation is attempted first in lesions that are most likely to
be responsible for the patient's ischemia. In targeted
lesions treated with stent implantation, the final angio-
graphic objective is a <30% residual stenosis, whereas, in
lesions treated with balloon PTCA (< 2.5 mm diameter
vessels or unable to deliver the stent), the final angio-
graphic objective is a <50% residual stenosis. In all treated
vessels, necessary means should be taken to achieve TIMI
grade-3 distal flow.
Paclitaxel-eluting stents will be used to treat all lesions
suitable for drug-eluting stent placement. A patient
should be treated with the same allocated stents in all
lesions during the course of the trial. The placement of
other than the allocated stent in a patient during the
course of the trial will be accepted when the allocated
stent cannot be deployed. If proper pre-dilation of the ves-
sel has been done but the stent still fails to reach the
lesion, the other type of study stent (ex, Coroflex
Please™stent in case of Taxus Liberte™ stent delivery fail-
ure, or vice versa) may be considered. If both study stents
cannot be delivered to the target lesion site, other com-
mercially approved drug-eluting stent or bare stent or bal-
loon PTCA may be used to complete optimal PCI. If the
non-target vessel is too large (>4.5 mm) to be stented with
allocated DES, bare-metal stent can be accepted. The
length and diameter of stent will not be restricted.
Recommendations for the adjunctive pharmacological therapy
Aspirin in dose 300 mg PO must be administered before
the index PCI, whether or not patient was taking Aspirin
at home. Aspirin will be continued at 75-325 mg PO
indefinitely. It will be recommended that patients receive
oral 300 mg to 600 mg loading dose of clopidogrel before
the index PCI if the patient was not taking clopidogrel
within 24 hours prior to admission. Post-procedure, the
treatment should be continued 75-150 mg PO per day at
least for 9 months. In case of intolerance/allergy to clopi-
dogrel, a loading dose of 500 mg of ticlopidine PO may
be administered, and the treatment should be continued
250 mg Ticlopidine BID per day. The use of additional
antiplatelet combination (i.e., cilostazol) will not be
allowed.
Follow up
Clinical follow-up will be at the planned time points
(Table 3). Follow-ups should be office visits, but tele-
phone contact will be allowed. Data collected during all
follow-up visits will include angina class and major
adverse ischemic, neurologic and bleeding events, includ-
ing re-hospitalization, re-catheterization and adverse
events/serious adverse events. Original source documents
must be submitted for any clinical events (death, re-inf-
arction, revascularization, stroke, or any other SAE within
12 months). If the patient is readmitted to a non-study
hospital, all possible efforts should be made to obtain
original source documents from that hospital. For all re-
infarctions, ECGs and cardiac enzymes (CPK, CK-MB, tro-
ponin) must be obtained and recorded.
Routine angiographic follow-up at 9 months (-3 month/
+3 months) will be recommended in this study. Any ear-
lier angiogram >30 days showing restenosis or thrombosis
(diameter stenosis >50%) will qualify as an endpoint ang-
iogram. If an angiogram is performed between 1 and 4
months and restenosis is not present in any study lesion,
the requirement for the 9-month angiogram has not been
met and thus the 9-month angiographic follow-up must
still be performed. Even when there was unexpected angi-
ography between 4 and 6 months and restenosis or
thrombosis were not present in any study lesion, the 9-
month angiographic follow-up must still be performed.
However, unscheduled angiograms > 6 months after pro-
cedure will be considered as 9-month follow-up angi-
ogram in final analysis. Copies of angiograms must be
submitted to the angiographic core laboratory of Seoul
National University Hospital Cardiovascular Center. Ang-
iograms to be received by the core laboratory include:
￿ The baseline angiogram from all randomized
patients;
￿ The 9-month routine follow-up angiograms in the
follow-up;
￿ All unscheduled follow-up angiograms in all rand-
omized patients over the 1 year period.
Table 3: Clinical follow-up
Follow-up time point ± days
1 month 14
4 months 30
9 months 3 months
12 months 30
2 years 30
3 years 30Trials 2009, 10:98 http://www.trialsjournal.com/content/10/1/98
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￿ Late angiographic follow-up will be recommended
at 18-24 months post PCI in patients enrolled at
selected centers.
Statistical Considerations
Sample size calculation
To test the hypothesis that Coroflex Please™ stent is non-
inferior to Taxus Liberte™ stent in 'clinically driven TVR at
9 months', we assumed an incidence of TVR as 8% for the
Taxus Liberte™ stent and less than 5% increases for the
Coroflex Please™ stent on the basis of results from TAXUS
II, TAXUS IV, ATLAS and PECOPS I trials with type I error
set at 0.05, statistical power set at 80%, sampling ratio of
Coroflex Please™ stent: Taxus Liberte™ stent at 2:1, and an
estimated drop out rate of 10% (for 9-month clinical fol-
low up). Based on above assumptions, we would need a
total of 915 patients, 610 patients in Coroflex Please™ arm
and 305 in Taxus Liberte™ arm.
To test the hypothesis that Coroflex™ Please stent is non-
inferior to Taxus Liberte™ stent in inhibiting 'neointimal
growth at 9 months angiographically', we assumed the
late loss as 0.4 ± 0.5 mm for the Taxus Liberte™ stent and
less than 0.15 mm increases for the Coroflex™ Please stent
on the basis of results from TAXUS II, TAXUS IV, ATLAS
and PECOPS I trials with type I error set at 0.05, statistical
power set at 80%, sampling ratio of Coroflex Please™
stent: Taxus Liberte™ stent at 2:1, and an estimated drop
out rate of 30% (for 9-month follow up angiography)
[6,7,12,14]. Based on above assumptions, we would need
a total of 450 patients, 300 patients in Coroflex Please™
arm and 150 in Taxus Liberte™ arm. Finally, based on
above calculations, we would need a total of 915 patients,
610 patients in Coroflex Please™ arm and 305 in Taxus
Liberte™ arm.
Statistical analyses
All primary and secondary endpoints will be analyzed
both on an intention-to-treat basis (all patients analyzed
as part of their assigned treatment group) and on per pro-
tocol basis (patients analyzed as part of their assigned
treatment group only if they actually received their
assigned treatment). For intention-to-treat analysis, all
patients who signed the written informed consent form
and are randomized in the study will be included in the
analysis sample, regardless of whether or not the correct
treatment was administered, or whether crossover
occurred. For the per protocol analysis, only enrolled
patients who actually received the assigned treatment will
be included in the analysis sample.
Baseline characteristics of study patients will be summa-
rized in terms of frequencies and percentages for categor-
ical variables and by means with standard deviations for
continuous variables. Categorical variables will be com-
pared by Fisher's exact test. Continuous variables will be
compared by the 2-sample t test. Cumulative event-free
survival will be summarized as Kaplan-Meier estimates. A
p value of 0.05 will be established as the level of statistical
significance for all tests.
The primary as well as secondary endpoints will be ana-
lyzed in prespecified subgroups. These subgroups include
patients with diabetes mellitus and long lesions.
Trial Organization
Executive Committee
The Executive Committee will be composed of the study
chairperson and the principal investigators of the investi-
gating centers. This committee will approve the final trial
design and protocol issued to the Data and Safety Moni-
toring Board (DSMB) and the clinical sites. This commit-
tee will also be responsible for reviewing the final results,
determining the methods of presentation and publica-
tion, and selection of secondary projects and publications
by members of the Steering Committee.
Data Safety Monitoring Board
The DSMB is composed of general and interventional car-
diologists, and a biostatistician. Names of the actual
members will not be announced, but may be provided to
the regulatory agency upon request. The DSMB will func-
tion in accordance with applicable regulatory guidelines.
The board members are independent and will not be par-
ticipating in the trial. The DSMB committee will review
the safety data from this study and make recommenda-
tions based on safety analyses of unanticipated device
effects (UADEs), serious adverse events (SAEs), protocol
deviation, device failures, and 30-day follow-up reports.
The frequency of the DSMB meetings will be determined
prior to study commencement. Additionally, the DSMB
may call a meeting at any time if there is reason to suspect
that safety is an issue. The DSMB is responsible for making
recommendations regarding any safety or compliance
issues throughout the course of the study and may recom-
mend the Executive Committee to modify or stop the
study. However, all final decisions regarding study modi-
fications rest with the Executive Committee.
All cumulative safety data will be reported to the DSMB
and reviewed on an ongoing basis throughout enrollment
and follow-up periods to ensure patient safety. Every
effort will be made to allow the DSMB to conduct an unbi-
ased review of patient safety information. All DSMB
reports will be made available to the appropriate agencies
upon request but will otherwise remain strictly confiden-
tial.
Prior to the DSMB's first review of the data, the DSMB
charter will be drafted. The plan will define the stoppingTrials 2009, 10:98 http://www.trialsjournal.com/content/10/1/98
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rules for stopping the trial for safety. The first meeting of
the DSMB will be sued for discussion of the protocol and
an understanding of all the protocol elements. The DSMB
will develop a consensus understanding of all trial end-
points and definitions used in the event adjudication
process. All DSMB reports will remain strictly confiden-
tial, but will be made available to the regulatory body
upon request.
Clinical Event Adjudication Committee
The Clinical Events Adjudication Committee (CEAC) is
comprised of interventional and non-interventional car-
diologists who are not participants in the study. The CEAC
is charged with the development of specific criteria used
for the categorization of clinical events and clinical end-
points in the study which are based on protocol. At the
onset of the trial, the CEAC will establish explicit rules
outlining the minimum amount of date required, and the
algorithm followed in order to classify a clinical event. All
members of the CEAC will be blinded to the primary
results of the trial.
The CEAC will meet regularly to review and adjudicate all
clinical events in which the required minimum data is
available. The Committee will also review and rule on all
deaths that occur throughout the trial.
Data Coordination and Site Management
Data coordination and site management services will be
performed by the Clinical Trials Center at Seoul National
University Hospital.
Ethical approval
This study has been approved by institutional review
board of Seoul National University Hospital.
Discussion
Drug-eluting stent (DES) has revolutionized the field of
interventional cardiology. Before DES era, restenosis in
the stented lesion was problematic. However, DES has sig-
nificantly reduced the rate of restenosis from 20-30% to
single digits as compared with bare-metal stents by inhib-
iting the growth of neointima after stenting[1,2,7] As a
consequence, nowadays interventional cardiologists are
increasingly treating patients with tougher and tougher
lesion, who would have otherwise undergone coronary
artery bypass surgery.
Paclitaxel, a liphophilic component from the Pacific yew
tree Taxus brevifolia, stabilizes the assembly of microtu-
bules by binding β-tubulin dimers and inhibiting their
polymerization [15-17] This drug inhibits arterial smooth
muscle cell proliferation and migration and matrix prolif-
eration resulting in inhibition of neointimal hyperplasia
after coronary artery stenting[18,19] Taxus is the first Pacl-
itaxel-eluting stent approved for human use. Its efficacy
and safety have been proven in numerous randomized
prospective trials including the TAXUS II, TAXUS IV and
TAXUS VI trials [6-9]
In TAXUS II trial, Taxus slow-release (SR) and Taxus mod-
erate-release (MR) showed a significant benefit over the
bare metal stent (BMS). Compared with late loss of 0.79 ±
0.45 mm and 0.77 ± 0.50 mm in the respective BMS con-
trol groups, Taxus SR and MR reduced late loss by 60.7%
and 61.0%, respectively (0.31 ± 0.38 mm and 0.30 ± 0.39
mm). Also, compared with percent in-stent net volume
obstruction of 23.17 ± 18.19% and 20.54 ± 16.68% in the
respective control groups, Taxus SR and MR showed a sig-
nificant favorable result of 7.84% ± 9.87% and 7.84 ±
9.66%. In terms of clinical efficacy as estimated by MACE
at 12 months, Taxus SR and MR showed 10.9% and 9.9%,
compared with 22.0% and 21.4% in the respective control
BMS groups.
Taxus IV trial was a prospective, randomized, double-
blind study in which 1314 patients were enrolled. The rate
of ischemia-driven target-vessel revascularization at nine
months was reduced from 12.0% in BMS group to 4.7%
in Taxus SR group. Target-lesion revascularization was
required in 3.0% of Taxus SR group, as compared with
11.3% of BMS group. Moreover, the rate of angiographic
restenosis was reduced from 26.6% in BMS group to 7.9%
in Taxus SR group.
In Taxus VI trial which was a prospective double-blind,
randomized trials assessing clinical and angiographic out-
comes of Taxus MR in the treatment of long, complex cor-
onary artery lesions, target-vessel revascularization rate at
9 months was 9.1% in the Taxus group and 19.4% in BMS
group. Target-lesion revascularization was reduced from
18.9% in the BMS group to 6.8% in the Taxus group. The
incidence of major adverse cardiac events was similar in
the 2 groups. Angiographically, in-stent late loss was
reduced 0.99 ± 0.585 mm to 0.39 ± 0.560 mm.
In Taxus ATLAS trial which was a global, prospective, sin-
gle-arm trial assessing non-inferiority of Taxus Liberte™
versus Taxus Express™ target-vessel revascularization rate
at 9 months was 8.0% in Taxus Liberte™ group and 7.1%
in Taxus Express™ group. Major adverse cardiac events rate
at 9 months was 10.5% and 11.0% respectively. In terms
of angiographic outcomes, in-stent late loss was 0.41 ±
0.54 mm versus 0.42 ± 0.54 mm.
The highly flexible Paclitaxel-eluting Coroflex Please stent
is a recently developed DES[13] This features stainless
steel struts covered by the non-absorbable polymer
Polysulfone® which is thermostable upto 180°C and thus
does not lose its physical properties during sterilization,Trials 2009, 10:98 http://www.trialsjournal.com/content/10/1/98
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transportation, nor storage. The release kinetics of the
drug ranges between Taxus SR and MR.
PECOPS I trial, which enrolled 97 patients, was multi-
center, prospective, nonrandomized trial to evaluate pro-
cedural, angiographic and clinical results of Coroflex
Please™ stent[12,13] The success rates of procedure and
study stent deployment were 100% and 94.8%. Binary in-
segment restenosis rate at 9 months was 7.8% as com-
pared with 7.9% in TAXUS IV trial. At 6 months, the
MACE rate was 8.0%, which was 8.5% and 7.8% for
TAXUS II MR and SR, respectively. These results of
Coroflex Please™ stent are within the range of other trials
with other Paclitaxel-eluting coronary stents. However,
PECOPS I was one-arm observational study and the lesion
more than 16 mm in length was excluded. Hence, we can-
not infer that Coroflex Please™ has comparable clinical
outcome for longer lesion. Furthermore, there have been
no previous head-to-head comparisons between
Coroflex™ Please and Taxus both of which elute paclitaxel.
In the current ECO-PLEASANT trial, we plan to directly
compare the angiographic and clinical efficacy of Coroflex
Please™ versus Taxus Liberte™ in coronary lesion includ-
ing long one. Moreover, we will compare the efficacy in
diabetic patients. We will mandate a 9-month follow up
coronary angiogram to compare the late luminal loss
between the two types of stents. Oculostenotic reflex may
become a confounding variable to re-intervention rate
since we expect a 9-month angiographic follow up of over
70%. To reduce the chance of falsely high rate of repeat
intervention, we will strictly differentiate clinically-driven
revascularization from oculostenotic reflex-driven repeat
intervention. In addition, all events will be independently
and judiciously adjudicated by the clinical event adjudica-
tion committee.
Recently 'late-catch up' phenomenon emerges as the hot
issue of DES. In animal studies, DES-treated segments
showed the delayed neointimal hyperplasia, which was
not definite in BMS-treated ones[20,21] Carter et al.
found that sirolimus-eluting stents did not maintain long-
term inhibition of neointimal hyperplasia because of the
polymer-induced inflammation or the delayed cellular
proliferation in the porcine coronary model[20] Farb et al.
showed that paclitaxel-eluting stents gave rise to delayed
healing and local toxicity which might be associated with
delayed neointimal hyperplasia[21] Park et al. demon-
strated that despite the 6-month suppression of intimal
hyperplasia after paclitaxel-eluting stents compared with
BMS, there was a "late-catch up" of intimal growth during
subsequent 18 months[22] Thus in this ECO-PLEASANT
trial, we will mandate an 18-24 months follow up coro-
nary angiogram at selected centers to answer the question;
"Is there late catch-up phenomenon in Coroflex™ Please
or Taxus Liberte™ stenting?"
In conclusion, this ECO-PLEASANT study is the first ran-
domized controlled trial of Coroflex Please™ stent, and it
will give us, for the first time, the insight regarding the
comparative efficacy of Coroflex Please™ stent with Taxus
Liberte™ stent, both of which do not have data in the situ-
ation of randomized controlled trial. Furthermore, we
include lesions with wide range of complexity in this trial,
which will give us valuable efficacy data easily extrapolat-
able to the real world practice. Finally, by adopting 18-24
months follow up coronary angiography in addition to 9
months one, we may be able to get the precious informa-
tion regarding 'late catch up phenomenon' in these stents.
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